Big pharma stocks near all-time highs as tech selloff pushes investors toward safer bets

The move reflects a rotation rather than a broad market rally. As technology shares come under pressure, some investors appear to be shifting toward large pharmaceutical names, which are often viewed as more defensive because demand for medicines tends to hold up across economic cycles. AbbVie, Eli Lilly and Gilead Sciences are each trading at or near record levels, suggesting the bid is concentrated in established, cash-generative companies rather than the sector as a whole.

For readers, the key question is whether this is a durable change in leadership or a short-term parking spot for capital. Drugmakers carry their own risks that a defensive label can obscure: patent cliffs, pricing pressure, clinical trial setbacks and regulatory decisions can all move shares sharply. Sector performance can also diverge widely between companies, so strength in a few names does not necessarily signal broad health.

What to watch: whether the tech pullback persists, how upcoming earnings and pipeline updates are received, and whether inflows into healthcare continue. Those signals will indicate if this rotation has staying power.